WallStreetZenWallStreetZen

NASDAQ: GTHX
G1 Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for GTHX

Based on 3 analysts offering 12 month price targets for G1 Therapeutics Inc.
Min Forecast
$3.00-17.58%
Avg Forecast
$4.33+19.04%
Max Forecast
$6.00+64.84%

Should I buy or sell GTHX stock?

Based on 3 analysts offering ratings for G1 Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GTHX stock forecasts and price targets.

GTHX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-25
lockedlocked$00.00+00.00%2024-06-25
lockedlocked$00.00+00.00%2024-02-13

1 of 1

Forecast return on equity

Is GTHX forecast to generate an efficient return?
Company
75.39%
Industry
70.82%
Market
80.39%
GTHX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GTHX forecast to generate an efficient return on assets?
Company
20.5%
Industry
30.66%
GTHX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GTHX earnings per share forecast

What is GTHX's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$0.50
Avg 2 year Forecast
-$0.22
Avg 3 year Forecast
$0.10

GTHX revenue forecast

What is GTHX's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$70.4M-16.22%
Avg 2 year Forecast
$93.5M+11.31%
Avg 3 year Forecast
$118.0M+40.37%
GTHX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GTHX revenue growth forecast

How is GTHX forecast to perform vs Biotechnology companies and vs the US market?
Company
11.9%
Industry
64.53%
Market
11.29%
GTHX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GTHX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GTHX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GTHX$3.64$4.33+19.04%Buy
LCTX$1.01$6.50+543.56%Strong Buy
OTLK$8.11$42.28+421.33%Strong Buy
PYXS$3.24$8.80+171.60%Strong Buy
MCRB$1.26$6.67+429.13%Strong Buy

G1 Therapeutics Stock Forecast FAQ

Is G1 Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: GTHX) stock is to Buy GTHX stock.

Out of 3 analysts, 0 (0%) are recommending GTHX as a Strong Buy, 3 (100%) are recommending GTHX as a Buy, 0 (0%) are recommending GTHX as a Hold, 0 (0%) are recommending GTHX as a Sell, and 0 (0%) are recommending GTHX as a Strong Sell.

If you're new to stock investing, here's how to buy G1 Therapeutics stock.

What is GTHX's earnings growth forecast for 2024-2026?

(NASDAQ: GTHX) G1 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.72%.

G1 Therapeutics's earnings in 2024 is -$30,591,000.On average, 5 Wall Street analysts forecast GTHX's earnings for 2024 to be -$26,349,821, with the lowest GTHX earnings forecast at -$31,891,649, and the highest GTHX earnings forecast at -$15,684,417. On average, 5 Wall Street analysts forecast GTHX's earnings for 2025 to be -$11,292,780, with the lowest GTHX earnings forecast at -$33,982,904, and the highest GTHX earnings forecast at $522,814.

In 2026, GTHX is forecast to generate $5,097,436 in earnings, with the lowest earnings forecast at -$5,750,953 and the highest earnings forecast at $20,912,556.

What is GTHX's revenue growth forecast for 2024-2026?

(NASDAQ: GTHX) G1 Therapeutics's forecast annual revenue growth rate of 11.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.53%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.29%.

G1 Therapeutics's revenue in 2024 is $84,041,000.On average, 4 Wall Street analysts forecast GTHX's revenue for 2024 to be $3,681,237,303, with the lowest GTHX revenue forecast at $3,225,761,825, and the highest GTHX revenue forecast at $4,192,444,744. On average, 4 Wall Street analysts forecast GTHX's revenue for 2025 to be $4,890,767,284, with the lowest GTHX revenue forecast at $3,549,906,449, and the highest GTHX revenue forecast at $5,941,780,087.

In 2026, GTHX is forecast to generate $6,167,478,852 in revenue, with the lowest revenue forecast at $4,050,239,361 and the highest revenue forecast at $9,287,266,297.

What is GTHX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GTHX) forecast ROA is 20.5%, which is lower than the forecast US Biotechnology industry average of 30.66%.

What is GTHX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year GTHX price target, the average GTHX price target is $4.33, with the highest GTHX stock price forecast at $6.00 and the lowest GTHX stock price forecast at $3.00.

On average, Wall Street analysts predict that G1 Therapeutics's share price could reach $4.33 by Jun 25, 2025. The average G1 Therapeutics stock price prediction forecasts a potential upside of 19.04% from the current GTHX share price of $3.64.

What is GTHX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: GTHX) G1 Therapeutics's current Earnings Per Share (EPS) is -$0.59. On average, analysts forecast that GTHX's EPS will be -$0.50 for 2024, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.30. On average, analysts forecast that GTHX's EPS will be -$0.22 for 2025, with the lowest EPS forecast at -$0.65, and the highest EPS forecast at $0.01. In 2026, GTHX's EPS is forecast to hit $0.10 (min: -$0.11, max: $0.40).

What is GTHX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GTHX) forecast ROE is 75.39%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.